Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.58
$0.063.95%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.91M | 2.93M | -9.61M | -14.69M | 6.85M |
| Total Depreciation and Amortization | 1.33M | 1.30M | 1.28M | 1.26M | 1.23M |
| Total Amortization of Deferred Charges | -- | -- | 59.00K | 119.00K | 187.00K |
| Total Other Non-Cash Items | 3.31M | 3.63M | 4.51M | 2.96M | -647.00K |
| Change in Net Operating Assets | -9.11M | 811.00K | 12.03M | 7.64M | -1.75M |
| Cash from Operations | -572.00K | 8.67M | 8.28M | -2.72M | 5.87M |
| Capital Expenditure | -990.00K | -1.28M | -1.11M | -1.47M | -1.50M |
| Sale of Property, Plant, and Equipment | 3.00K | 3.00K | 3.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.50M | 5.50M | 20.30M | -20.54M | -20.55M |
| Cash from Investing | 4.52M | 4.22M | 19.20M | -22.01M | -22.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.42M | -20.42M | -20.42M | -- | -- |
| Issuance of Common Stock | 8.70M | 3.63M | 0.00 | 0.00 | 10.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.72M | -16.79M | -20.42M | 0.00 | 10.43M |
| Foreign Exchange rate Adjustments | 24.00K | 25.00K | -56.00K | -63.00K | -79.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.75M | -3.87M | 7.00M | -24.79M | -5.83M |